Unknown PHASE2 INTERVENTIONAL 2-arm NCT04226898

Synbiotic Compound to Reduce Symptoms of Schizophrenia

A Double-Blind Placebo-Controlled Trial of the Synbiotic Compound Probio-Tec ABCG for Schizophrenia Patients With and Without Elevated Markers of Gastrointestinal Inflammation

Sponsor: Sheppard Pratt Health System

Conditions Schizoaffective Disorder Schizophrenia

Interventions Inert Compound Synbiotic Supplement

Updated 9 times since 2020 Last updated: Apr 19, 2023 Started: Feb 21, 2022 Primary completion: Sep 30, 2024 Completion: Jan 31, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Schizoaffective Disorder and Schizophrenia and is currently ongoing. Sheppard Pratt Health System leads this study, which shows 9 recorded versions since 2022 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Status Flow

Change History

9 versions recorded

May 2025 — Present [monthly]

Unknown PHASE2

Status: Recruiting → Unknown
Sep 2024 — May 2025 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
May 2023 — Jul 2024 [monthly]

Recruiting PHASE2

Status: Enrolling By Invitation → Recruiting
Apr 2022 — May 2023 [monthly]

Enrolling By Invitation PHASE2

Status: Not Yet Recruiting → Enrolling By Invitation

▶ Show 4 earlier versions

Oct 2021 — Apr 2022 [monthly]

Not Yet Recruiting PHASE2
Jan 2021 — Oct 2021 [monthly]

Not Yet Recruiting PHASE2
Nov 2020 — Jan 2021 [monthly]

Not Yet Recruiting PHASE2
Feb 2020 — Nov 2020 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sheppard Pratt Health System

Data source: Sheppard Pratt Health System

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Baltimore, United States